Leukemia Clinical Trials in Baltimore

Showing 881-899 of 899 trials

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

NCT00363974

The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy (ara-C and idarubicin) in patients with refractory or relapsed AML.

Leukemia, Myelomonocytic, Acute

Aegera Therapeutics54 participantsStarted Oct 2005

Los Angeles, California, United States • Los Angeles, California, United States • Chicago, Illinois, United States +4 more locations

COMPLETEDPhase 2< 1 mile

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969

The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

Small Cell Lung Cancer

Celgene Corporation76 participantsStarted Apr 2006

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Berkeley, California, United States +44 more locations

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Leukemia Trials in Other Cities

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Phase I Study of Intrathecal Topotecan

A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia

Mechanism of Thrombocytopenia in Infants

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

CP-481,715 Nickel Allergy Study.

Amonafide in Combination With Cytarabine in Secondary AML

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Other Conditions in Baltimore